Literature DB >> 11854530

Attenuation of thermal nociception and hyperalgesia by VR1 blockers.

Carolina García-Martinez1, Marc Humet, Rosa Planells-Cases, Ana Gomis, Marco Caprini, Felix Viana, Elvira De La Pena, Francisco Sanchez-Baeza, Teresa Carbonell, Carmen De Felipe, Enrique Pérez-Paya, Carlos Belmonte, Angel Messeguer, Antonio Ferrer-Montiel.   

Abstract

Vanilloid receptor subunit 1 (VR1) appears to play a critical role in the transduction of noxious chemical and thermal stimuli by sensory nerve endings in peripheral tissues. Thus, VR1 antagonists are useful compounds to unravel the contribution of this receptor to pain perception, as well as to induce analgesia. We have used a combinatorial approach to identify new, nonpeptidic channel blockers of VR1. Screening of a library of trimers of N-alkylglycines resulted in the identification of two molecules referred to as DD161515 [N-[2-(2-(N-methylpyrrolidinyl)ethyl]glycyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-dichlorophenethyl)glycinamide] and DD191515 [[N-[3-(N,N-diethylamino)propyl]glycyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid-related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated pain and neurogenic inflammation evoked by intradermal injection of capsaicin into the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo. These trialkylglycine-based, noncompetitive VR1 antagonists may likely be developed into analgesics to treat inflammatory pain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854530      PMCID: PMC122372          DOI: 10.1073/pnas.022285899

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  The vanilloid receptor: a molecular gateway to the pain pathway.

Authors:  M J Caterina; D Julius
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 2.  Blood-brain barrier biology and methodology.

Authors:  W M Pardridge
Journal:  J Neurovirol       Date:  1999-12       Impact factor: 2.643

3.  Can peptides be mimicked?

Authors: 
Journal:  Drug Discov Today       Date:  2000-08       Impact factor: 7.851

Review 4.  New perspectives on enigmatic vanilloid receptors.

Authors:  A Szallasi; V Di Marzo
Journal:  Trends Neurosci       Date:  2000-10       Impact factor: 13.837

Review 5.  Engineering the NMDA receptor channel lining.

Authors:  A V Ferrer-Montiel; M Montal
Journal:  Methods Mol Biol       Date:  1999

6.  Identification of an aspartic residue in the P-loop of the vanilloid receptor that modulates pore properties.

Authors:  C García-Martínez; C Morenilla-Palao; R Planells-Cases; J M Merino; A Ferrer-Montiel
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

7.  Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia.

Authors:  J B Davis; J Gray; M J Gunthorpe; J P Hatcher; P T Davey; P Overend; M H Harries; J Latcham; C Clapham; K Atkinson; S A Hughes; K Rance; E Grau; A J Harper; P L Pugh; D C Rogers; S Bingham; A Randall; S A Sheardown
Journal:  Nature       Date:  2000-05-11       Impact factor: 49.962

8.  The cloned capsaicin receptor integrates multiple pain-producing stimuli.

Authors:  M Tominaga; M J Caterina; A B Malmberg; T A Rosen; H Gilbert; K Skinner; B E Raumann; A I Basbaum; D Julius
Journal:  Neuron       Date:  1998-09       Impact factor: 17.173

9.  Swelling-activated calcium signalling in cultured mouse primary sensory neurons.

Authors:  F Viana; E de la Peña; B Pecson; R F Schmidt; C Belmonte
Journal:  Eur J Neurosci       Date:  2001-02       Impact factor: 3.386

10.  Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors.

Authors:  D Melck; T Bisogno; L De Petrocellis; H Chuang; D Julius; M Bifulco; V Di Marzo
Journal:  Biochem Biophys Res Commun       Date:  1999-08-19       Impact factor: 3.575

View more
  41 in total

1.  Identification of SNARE complex modulators that inhibit exocytosis from an alpha-helix-constrained combinatorial library.

Authors:  Clara Blanes-Mira; Maria T Pastor; Elvira Valera; Gregorio Fernández-Ballester; Jaime M Merino; Luis M Gutierrez; Enrique Perez-Payá; Antonio Ferrer-Montiel
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

2.  TRP vanilloid 2 knock-out mice are susceptible to perinatal lethality but display normal thermal and mechanical nociception.

Authors:  Una Park; Nisha Vastani; Yun Guan; Srinivasa N Raja; Martin Koltzenburg; Michael J Caterina
Journal:  J Neurosci       Date:  2011-08-10       Impact factor: 6.167

3.  Analgesic effect of a polypeptide inhibitor of the TRPV1 receptor in noxious heat pain models.

Authors:  Y A Andreev; S A Kozlov; E P Kozlovskaya; E V Grishin
Journal:  Dokl Biochem Biophys       Date:  2009 Jan-Feb       Impact factor: 0.788

4.  Physiology and pharmacology of the vanilloid receptor.

Authors:  Angel Messeguer; Rosa Planells-Cases; Antonio Ferrer-Montiel
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

5.  Analgesic compound from sea anemone Heteractis crispa is the first polypeptide inhibitor of vanilloid receptor 1 (TRPV1).

Authors:  Yaroslav A Andreev; Sergey A Kozlov; Sergey G Koshelev; Ekaterina A Ivanova; Margarita M Monastyrnaya; Emma P Kozlovskaya; Eugene V Grishin
Journal:  J Biol Chem       Date:  2008-06-25       Impact factor: 5.157

6.  Solid-phase synthesis of a library of amphipatic hydantoins. Discovery of new hits for TRPV1 blockade.

Authors:  Guillermo Gerona-Navarro; Rosario González-Muñiz; Asia Fernández-Carvajal; José M González-Ros; Antonio Ferrer-Montiel; Cristina Carreño; Fernando Albericio; Miriam Royo
Journal:  ACS Comb Sci       Date:  2011-07-08       Impact factor: 3.784

7.  Pharmacological and functional properties of TRPM8 channels in prostate tumor cells.

Authors:  Maria Valero; Cruz Morenilla-Palao; Carlos Belmonte; Felix Viana
Journal:  Pflugers Arch       Date:  2010-11-05       Impact factor: 3.657

8.  Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.

Authors:  Bogna Ignatowska-Jankowska; Jenny L Wilkerson; Mohammed Mustafa; Rehab Abdullah; Micah Niphakis; Jenny L Wiley; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2015-03-11       Impact factor: 4.030

9.  Jejunal afferent nerve sensitivity in wild-type and TRPV1 knockout mice.

Authors:  Weifang Rong; Kirk Hillsley; John B Davis; Gareth Hicks; Wendy J Winchester; David Grundy
Journal:  J Physiol       Date:  2004-08-26       Impact factor: 5.182

10.  Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity.

Authors:  Ma Carme Mulero; Anna Aubareda; Mar Orzáez; Joaquim Messeguer; Eva Serrano-Candelas; Sergio Martínez-Hoyer; Angel Messeguer; Enrique Pérez-Payá; Mercè Pérez-Riba
Journal:  J Biol Chem       Date:  2009-02-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.